Cefepime MIC as a predictor of the extended-spectrum β-lactamase type in Klebsiella pneumoniae, Taiwan

Wen Liang Yu, Michael A. Pfaller, Patricia L. Winokur, Ronald N. Jones

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

To guide selection of carbapenems or fourth-generation cephalosporins as therapy, 110 Klebsiella pneumoniae isolates with extended-spectrum β-lactamases from Taiwan were characterized by phenotypic (MICs), molecular, and chemical methods. MIC patterns of ceftazidime and cefepime clearly differentiate strains treatable by cefepime and those capable of efficiently hydrolyzing available cephalosporins (CTX-M series and SHV-types). Continued use of cefepime appears to be a treatment option in cases for which MIC results are available and interpreted by the criteria presented.

Original languageEnglish
Pages (from-to)522-524
Number of pages3
JournalEmerging Infectious Diseases
Volume8
Issue number5
Publication statusPublished - 2002
Externally publishedYes

Fingerprint

Klebsiella pneumoniae
Taiwan
Cephalosporins
Carbapenems
Ceftazidime
cefepime
Therapeutics

ASJC Scopus subject areas

  • Microbiology (medical)

Cite this

Cefepime MIC as a predictor of the extended-spectrum β-lactamase type in Klebsiella pneumoniae, Taiwan. / Yu, Wen Liang; Pfaller, Michael A.; Winokur, Patricia L.; Jones, Ronald N.

In: Emerging Infectious Diseases, Vol. 8, No. 5, 2002, p. 522-524.

Research output: Contribution to journalArticle

Yu, Wen Liang ; Pfaller, Michael A. ; Winokur, Patricia L. ; Jones, Ronald N. / Cefepime MIC as a predictor of the extended-spectrum β-lactamase type in Klebsiella pneumoniae, Taiwan. In: Emerging Infectious Diseases. 2002 ; Vol. 8, No. 5. pp. 522-524.
@article{2e590ba9755d4048a23e5c2a8a926fb5,
title = "Cefepime MIC as a predictor of the extended-spectrum β-lactamase type in Klebsiella pneumoniae, Taiwan",
abstract = "To guide selection of carbapenems or fourth-generation cephalosporins as therapy, 110 Klebsiella pneumoniae isolates with extended-spectrum β-lactamases from Taiwan were characterized by phenotypic (MICs), molecular, and chemical methods. MIC patterns of ceftazidime and cefepime clearly differentiate strains treatable by cefepime and those capable of efficiently hydrolyzing available cephalosporins (CTX-M series and SHV-types). Continued use of cefepime appears to be a treatment option in cases for which MIC results are available and interpreted by the criteria presented.",
author = "Yu, {Wen Liang} and Pfaller, {Michael A.} and Winokur, {Patricia L.} and Jones, {Ronald N.}",
year = "2002",
language = "English",
volume = "8",
pages = "522--524",
journal = "Emerging Infectious Diseases",
issn = "1080-6040",
publisher = "Centers for Disease Control and Prevention (CDC)",
number = "5",

}

TY - JOUR

T1 - Cefepime MIC as a predictor of the extended-spectrum β-lactamase type in Klebsiella pneumoniae, Taiwan

AU - Yu, Wen Liang

AU - Pfaller, Michael A.

AU - Winokur, Patricia L.

AU - Jones, Ronald N.

PY - 2002

Y1 - 2002

N2 - To guide selection of carbapenems or fourth-generation cephalosporins as therapy, 110 Klebsiella pneumoniae isolates with extended-spectrum β-lactamases from Taiwan were characterized by phenotypic (MICs), molecular, and chemical methods. MIC patterns of ceftazidime and cefepime clearly differentiate strains treatable by cefepime and those capable of efficiently hydrolyzing available cephalosporins (CTX-M series and SHV-types). Continued use of cefepime appears to be a treatment option in cases for which MIC results are available and interpreted by the criteria presented.

AB - To guide selection of carbapenems or fourth-generation cephalosporins as therapy, 110 Klebsiella pneumoniae isolates with extended-spectrum β-lactamases from Taiwan were characterized by phenotypic (MICs), molecular, and chemical methods. MIC patterns of ceftazidime and cefepime clearly differentiate strains treatable by cefepime and those capable of efficiently hydrolyzing available cephalosporins (CTX-M series and SHV-types). Continued use of cefepime appears to be a treatment option in cases for which MIC results are available and interpreted by the criteria presented.

UR - http://www.scopus.com/inward/record.url?scp=0036093612&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036093612&partnerID=8YFLogxK

M3 - Article

C2 - 11996691

AN - SCOPUS:0036093612

VL - 8

SP - 522

EP - 524

JO - Emerging Infectious Diseases

JF - Emerging Infectious Diseases

SN - 1080-6040

IS - 5

ER -